AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19101632 — intervention group
Group type: EXPERIMENTAL
Intervention: Itopride hydrochloride
Number of subjects: 0
Study 16467656 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren (300 mg)
Number of subjects: 0
Study 16467656 — intervention group
Group type: COMPARATOR
Intervention: Valsartan (160 mg)
Number of subjects: 0
Study 12865453 — intervention group
Group type: COMPARATOR
Intervention: Bilateral oophorectomy
Number of subjects: 1124
Study 12865453 — intervention group
Group type: COMPARATOR
Intervention: Other gynecologic surgeries
Number of subjects: 1124
Study 12865453 — intervention group
Group type: COMPARATOR
Intervention: Surgery to remove some ovarian tissue
Number of subjects: 1124
Study 10853168 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 degrees lateral‐wedged insole
Number of subjects: 17
Study 10853168 — intervention group
Group type: COMPARATOR
Intervention: No insole (control condition)
Number of subjects: 17
Study 9359709 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant herpes simplex virus type 2 glycoproteins D and B vaccine in MF59 adjuvant
Number of subjects: 0
Study 9359709 — intervention group
Group type: COMPARATOR
Intervention: MF59 alone (placebo)
Number of subjects: 0
Study 8269444 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose bisoprolol/HCTZ 6.25 mg
Number of subjects: 0
Study 8269444 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy and placebo
Number of subjects: 0
Study 3946169 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral amiodarone (30 mg/kg)
Number of subjects: 50
Study 3946169 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (no intervention)
Number of subjects: 50
Study 3946169 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral amiodarone
Number of subjects: 50
Study 31499247 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced EUS
Number of subjects: 101
Study 31499247 — intervention group
Group type: COMPARATOR
Intervention: Unenhanced EUS
Number of subjects: 101
Study 30461306 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab in combination with chemoradiotherapy (CRT)
Number of subjects: 0
Study 30461306 — intervention group
Group type: COMPARATOR
Intervention: Placebo in combination with chemoradiotherapy (CRT)
Number of subjects: 0
Study 28213776 — intervention group
Group type: EXPERIMENTAL
Intervention: Target Controlled Infusion (TCI) sedation endoscopy (TCI-DISE)
Number of subjects: 173
Study 28213776 — intervention group
Group type: COMPARATOR
Intervention: Conventional DISE (C-DISE)
Number of subjects: 173
Study 28213776 — intervention group
Group type: EXPERIMENTAL
Intervention: Target Controlled Infusion (TCI-DISE)
Number of subjects: 173
Study 25127514 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified spinal mobilisation with leg movement (SMWLM)
Number of subjects: 45
Study 25127514 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 25127514 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 45
Study 22878857 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care intervention for anxiety disorders
Number of subjects: 124
Study 22878857 — intervention group
Group type: COMPARATOR
Intervention: Usual care by the doctor
Number of subjects: 124
Study 22092126 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl 0 mcg/kg (F0)
Number of subjects: 60
Study 22092126 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 1 mcg/kg (F1)
Number of subjects: 60
Study 22092126 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 1.5 mcg/kg (F1.5)
Number of subjects: 60
Study 22092126 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 2 mcg/kg (F2)
Number of subjects: 60
Study 19035530 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural direct effect bounds
Number of subjects: 0
Study 19035530 — intervention group
Group type: COMPARATOR
Intervention: Controlled direct effect bounds
Number of subjects: 0
Study 17035445 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal trivalent, live attenuated, cold‐adapted influenza virus vaccine (TC)
Number of subjects: 2215
Study 17035445 — intervention group
Group type: COMPARATOR
Intervention: Intranasal placebo (TP)
Number of subjects: 2215
Study 17035445 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory‐documented influenza (LDI)‐caused illness
Number of subjects: 2215
Study 17035445 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute respiratory illness
Number of subjects: 2215
Study 17035445 — intervention group
Group type: EXPERIMENTAL
Intervention: No illness
Number of subjects: 2215
Study 15167171 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenecteplase
Number of subjects: 1639
Study 15167171 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin or unfractionated heparin (control)
Number of subjects: 1639
Study 11225418 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 mA or 150 mA tube current in group A (weight < 60 kg)
Number of subjects: 77
Study 11225418 — intervention group
Group type: EXPERIMENTAL
Intervention: 150, 175 or 200 mA tube current in group B (weight 60-80 kg)
Number of subjects: 77
Study 11225418 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mA tube current in group C (weight > 80 kg)
Number of subjects: 77
Study 11225418 — intervention group
Group type: EXPERIMENTAL
Intervention: Body weight adjusted tube current
Number of subjects: 77
Study 9430084 — intervention group
Group type: EXPERIMENTAL
Intervention: A16 soybean oil
Number of subjects: 15
Study 9430084 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial soybean oil
Number of subjects: 15
Study 9430084 — intervention group
Group type: COMPARATOR
Intervention: Coconut oil
Number of subjects: 15
Study 8213578 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (1 mg infusion followed by oral treatment to a target dose of 20 mg/day)
Number of subjects: 428
Study 8213578 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 428
Study 3315271 — intervention group
Group type: EXPERIMENTAL
Intervention: BID (twice-daily, equally divided 12 hr)
Number of subjects: 10
Study 3315271 — intervention group
Group type: EXPERIMENTAL
Intervention: OD-PM (once-daily evening)
Number of subjects: 10
Study 3315271 — intervention group
Group type: EXPERIMENTAL
Intervention: OD-AM (once-daily morning)
Number of subjects: 10
Study 3315271 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 10
Study 29958328 — intervention group
Group type: EXPERIMENTAL
Intervention: Adequately physically active
Number of subjects: 5611
Study 29958328 — intervention group
Group type: EXPERIMENTAL
Intervention: Inadequately physically active
Number of subjects: 5611
Study 29958328 — intervention group
Group type: COMPARATOR
Intervention: Inactive
Number of subjects: 5611
Study 27687373 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep NMB (posttetanic count, < 5)
Number of subjects: 76
Study 27687373 — intervention group
Group type: COMPARATOR
Intervention: Moderate NMB (train‐of‐four count, 1‐3)
Number of subjects: 76
Study 25175480 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol/fluticasone propionate combination inhaler (SFC)
Number of subjects: 0
Study 25175480 — intervention group
Group type: COMPARATOR
Intervention: No FP dose change
Number of subjects: 0
Study 25175480 — intervention group
Group type: COMPARATOR
Intervention: Increased FP dose
Number of subjects: 0
Study 22759324 — intervention group
Group type: COMPARATOR
Intervention: ST + placebo
Number of subjects: 227
Study 22759324 — intervention group
Group type: EXPERIMENTAL
Intervention: ST + LF + PB
Number of subjects: 227
Study 22759324 — intervention group
Group type: EXPERIMENTAL
Intervention: ST + PB
Number of subjects: 227
Study 22759324 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (ST + placebo, ST + LF + PB, ST + PB)
Number of subjects: 227
Study 20083352 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine injection
Number of subjects: 20
Study 20083352 — intervention group
Group type: COMPARATOR
Intervention: Saline injection
Number of subjects: 20
Study 20083352 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical clonazepam
Number of subjects: 20
Study 20083352 — intervention group
Group type: EXPERIMENTAL
Intervention: HAD score
Number of subjects: 20
Study 18724209 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal baclofen (ITB)
Number of subjects: 100
Study 18724209 — intervention group
Group type: COMPARATOR
Intervention: Control (no ITB treatment)
Number of subjects: 100
Study 15910297 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) administered at a daily oral dose of 2 x 1000 mg for the first 6 postoperative months, tapered within 2 weeks thereafter.
Number of subjects: 86
Study 15910297 — intervention group
Group type: COMPARATOR
Intervention: Control group received fluocortolon and topical prednisolone acetate, no specific intervention mentioned.
Number of subjects: 86
Study 15910297 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) group.
Number of subjects: 86
Study 15910297 — intervention group
Group type: COMPARATOR
Intervention: Control group.
Number of subjects: 86
Study 15910297 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups experienced side effects, particularly gastroenterotoxicity, tachycardia, arthralgia, or systemic infections.
Number of subjects: 86
Study 11156812 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion (up to 200 mg b.i.d.)
Number of subjects: 40
Study 11156812 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 9625292 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin plus nicotinamide (0.5 g, three tablets/day)
Number of subjects: 18
Study 9625292 — intervention group
Group type: EXPERIMENTAL
Intervention: Current sulphonylureas plus nicotinamide (0.5 g, three tablets/day)
Number of subjects: 18
Study 9625292 — intervention group
Group type: COMPARATOR
Intervention: Insulin plus placebo (3 tablets/day)
Number of subjects: 18
Study 7836197 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline (5 mg/kg)
Number of subjects: 9
Study 7836197 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 7836197 — intervention group
Group type: COMPARATOR
Intervention: Dipyridamole (0.6 mg/kg)
Number of subjects: 9
Study 3282078 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa-2B therapy for an additional 6 months (18 months total)
Number of subjects: 90
Study 3282078 — intervention group
Group type: COMPARATOR
Intervention: No further therapy after 12 months of interferon alfa-2B
Number of subjects: 90
Study 3282078 — intervention group
Group type: EXPERIMENTAL
Intervention: Re-treatment with interferon alfa-2B after relapse
Number of subjects: 90
Study 3282078 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa-2B therapy (standard dose of 2 X 10(6) U/m2 sc three times weekly)
Number of subjects: 90
Study 31482404 — intervention group
Group type: EXPERIMENTAL
Intervention: Orange color room
Number of subjects: 0
Study 31482404 — intervention group
Group type: COMPARATOR
Intervention: White color room
Number of subjects: 0
Study 29409133 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg
Number of subjects: 292
Study 29409133 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 292
Study 29409133 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 292
Study 29409133 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg (anti-TNF-naive)
Number of subjects: 292
Study 29409133 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg (anti-TNF-naive)
Number of subjects: 292
Study 29409133 — intervention group
Group type: COMPARATOR
Intervention: Placebo (anti-TNF-naive)
Number of subjects: 292
Study 29409133 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg (anti-TNF-IR)
Number of subjects: 292
Study 29409133 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg (anti-TNF-IR)
Number of subjects: 292
Study 29409133 — intervention group
Group type: COMPARATOR
Intervention: Placebo (anti-TNF-IR)
Number of subjects: 292
Study 29409133 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg and 150 mg
Number of subjects: 292
Study 29409133 — intervention group
Group type: EXPERIMENTAL
Intervention: MDA responders
Number of subjects: 292
Study 28013272 — intervention group
Group type: EXPERIMENTAL
Intervention: CSC-T (8-session, group-based comprehensive smoking cessation and trauma management treatment)
Number of subjects: 90
Study 28013272 — intervention group
Group type: COMPARATOR
Intervention: CSC (comprehensive smoking cessation alone)
Number of subjects: 90
Study 23542112 — intervention group
Group type: EXPERIMENTAL
Intervention: Adult CHD patients with a >3-year gap in cardiology care
Number of subjects: 922
Study 23542112 — intervention group
Group type: EXPERIMENTAL
Intervention: Adult CHD patients with mild, moderate, and severe disease
Number of subjects: 922
Study 23542112 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinic location
Number of subjects: 922
Study 23542112 — intervention group
Group type: EXPERIMENTAL
Intervention: Common reasons for gaps in care
Number of subjects: 922
Study 23542112 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for returning to care
Number of subjects: 922
Study 21612744 — intervention group
Group type: EXPERIMENTAL
Intervention: Amikacin 125 ‐ 1,000 mg once‐daily or every‐other‐day
Number of subjects: 305
Study 20115931 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 322
Study 20115931 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet
Number of subjects: 322
Study 20115931 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 322
Study 17183433 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct transfer to PCI centre from on-site (group 1)
Number of subjects: 42
Study 17183433 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfer after initial treatment in local emergency room (group 2)
Number of subjects: 42
Study 17183433 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfer after initial treatment in local emergency room (group 3)
Number of subjects: 42
Study 17183433 — intervention group
Group type: COMPARATOR
Intervention: Overall rate of Major Adverse Cardiac Events (MACE)
Number of subjects: 42
Study 15271158 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fluid warmer set at 38.5 degrees C on the dialysate and 1 L/hour of replacement fluid lines
Number of subjects: 60
Study 15271158 — intervention group
Group type: COMPARATOR
Intervention: No fluid warmer
Number of subjects: 60
Study 15271158 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (with and without fluid warmer)
Number of subjects: 60
Study 15271158 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower baseline temperature
Number of subjects: 60
Study 15271158 — intervention group
Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 60
Study 11785857 — intervention group
Group type: EXPERIMENTAL
Intervention: Vignette patients with risk factors for preterm birth
Number of subjects: 301
Study 11785857 — intervention group
Group type: COMPARATOR
Intervention: Vignette patients without risk factors for preterm birth
Number of subjects: 301
Study 9377662 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostatic carcinoma (PC)
Number of subjects: 38
Study 9377662 — intervention group
Group type: EXPERIMENTAL
Intervention: Benign prostatic hyperplasia (BPH)
Number of subjects: 38
Study 9377662 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 38
Study 7898095 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors
Number of subjects: 0
Study 7898095 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium antagonists
Number of subjects: 0
Study 7898095 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic antihypertensive therapy
Number of subjects: 0
Study 3390235 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) - Counselling by a trained assistant nurse and a physician
Number of subjects: 120
Study 3390235 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG) - No specific intervention mentioned
Number of subjects: 120
Study 31556524 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 50
Study 28394459 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (500 mg BID)
Number of subjects: 13
Study 28394459 — intervention group
Group type: COMPARATOR
Intervention: Placebo (719 mg maltodextrin)
Number of subjects: 13
Study 28394459 — intervention group
Group type: COMPARATOR
Intervention: Normoxia
Number of subjects: 13
Study 26392152 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat, high-AGE (HFHA) diet
Number of subjects: 19
Study 26392152 — intervention group
Group type: COMPARATOR
Intervention: Low-fat, high-AGE (LFHA) diet
Number of subjects: 19
Study 26392152 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 19
Study 24138400 — intervention group
Group type: EXPERIMENTAL
Intervention: VR training
Number of subjects: 12
Study 24138400 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 12
Study 21700360 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% minoxidil topical foam (MTF) once daily
Number of subjects: 113
Study 21700360 — intervention group
Group type: COMPARATOR
Intervention: 2% minoxidil topical solution (MTS) twice daily
Number of subjects: 113
Study 17901091 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan
Number of subjects: 613
Study 17901091 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitaxsentan
Number of subjects: 613
Study 17901091 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 613
Study 17901091 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 613
Study 22146488 — intervention group
Group type: EXPERIMENTAL
Intervention: Active breathing training program
Number of subjects: 19
Study 22146488 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 19
Study 15644834 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 61
Study 15644834 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 12590213 — intervention group
Group type: EXPERIMENTAL
Intervention: rhBMP-2 on an absorbable collagen sponge
Number of subjects: 42
Study 12590213 — intervention group
Group type: COMPARATOR
Intervention: Autogenous iliac crest bone graft
Number of subjects: 42
Study 9607117 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual alcohol intake
Number of subjects: 55
Study 9607117 — intervention group
Group type: COMPARATOR
Intervention: Low alcohol beer
Number of subjects: 55
Study 7638994 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathoracic local anesthetics via intrapleural catheter (IPCs)
Number of subjects: 42
Study 7638994 — intervention group
Group type: COMPARATOR
Intervention: Systemic narcotic medications
Number of subjects: 42
Study 2507224 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral feeding via needle catheter jejunostomy (NCJ) starting 12 hours postoperatively, advanced to 100-125 ml/h of full-strength diet
Number of subjects: 123
Study 2507224 — intervention group
Group type: COMPARATOR
Intervention: Control group (no enteral nutrition during the first 5 days)
Number of subjects: 123
Study 782777 — intervention group
Group type: EXPERIMENTAL
Intervention: Amine fluoride daily
Number of subjects: 468
Study 782777 — intervention group
Group type: COMPARATOR
Intervention: Acidulated phosphate fluoride daily
Number of subjects: 468
Study 782777 — intervention group
Group type: COMPARATOR
Intervention: Amine fluoride weekly
Number of subjects: 468
Study 782777 — intervention group
Group type: COMPARATOR
Intervention: Placebo daily
Number of subjects: 468
Study 782777 — intervention group
Group type: COMPARATOR
Intervention: Placebo weekly
Number of subjects: 468
Study 31780025 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin (500 mg/d)
Number of subjects: 60
Study 31780025 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 27847235 — intervention group
Group type: EXPERIMENTAL
Intervention: FBR1 (HRT of 8h) with ethanol and nitrate addition (Phase II)
Number of subjects: 2
Study 27847235 — intervention group
Group type: EXPERIMENTAL
Intervention: FBR1 (HRT of 8h) with nitrate (Phase IV)
Number of subjects: 2
Study 27847235 — intervention group
Group type: COMPARATOR
Intervention: FBR1 (HRT of 8h) without nitrate (Phase V)
Number of subjects: 2
Study 27847235 — intervention group
Group type: EXPERIMENTAL
Intervention: FBR2 (HRT of 12h) with ethanol and nitrate addition (Phase I)
Number of subjects: 2
Study 27847235 — intervention group
Group type: EXPERIMENTAL
Intervention: FBR2 (HRT of 12h)
Number of subjects: 2
Study 27847235 — intervention group
Group type: EXPERIMENTAL
Intervention: FBR1 (HRT of 8h) without ethanol (Phase IV)
Number of subjects: 2
Study 27847235 — intervention group
Group type: COMPARATOR
Intervention: FBR1 (HRT of 8h) with ethanol (Phase II)
Number of subjects: 2
Study 25263527 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D bioresorbable PCL scaffold
Number of subjects: 13
Study 25263527 — intervention group
Group type: COMPARATOR
Intervention: No space filler (control)
Number of subjects: 13
Study 23429913 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK961081 (400 μg once daily)
Number of subjects: 436
Study 23429913 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK961081 (200 μg twice daily)
Number of subjects: 436
Study 23429913 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 436
Study 23429913 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol
Number of subjects: 436
Study 21679318 — intervention group
Group type: EXPERIMENTAL
Intervention: Skiing intervention (12 weeks, average of 28.5 days of guided skiing)
Number of subjects: 27
Study 21679318 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=20; age: 67.3 ± 4.4 years)
Number of subjects: 27
Study 18094013 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone therapy
Number of subjects: 0
Study 16877299 — intervention group
Group type: EXPERIMENTAL
Intervention: D-Ala1-peptide T-amide (DAPTA) at a dose of 2 mg three times per day (tid)
Number of subjects: 149
Study 16877299 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study 12890601 — intervention group
Group type: COMPARATOR
Intervention: Mother-daughter sexual risk communication
Number of subjects: 219
Study 10638883 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of the object (participants reached forward with the impaired arm to scoop coins)
Number of subjects: 39